Oncology

A gene expression test is changing melanoma care by providing risk data beyond traditional staging, enabling more tailored treatment for patients.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

A promising oral therapy for a rare, aggressive lung cancer is now under review in Europe, offering a new option for patients with limited treatments.

Eurofins Viracor's new assay delivers rapid insights into CAR T-cell performance, promising faster, more personalized decisions for cancer patients.

A new US-China partnership secures a vital supply of Lu-177, aiming to accelerate the development and delivery of targeted cancer therapies in China.

The company's B-cell cancer assay has achieved stringent IVDR certification, navigating a complex landscape and gaining a key edge in Europe's market.

Ono Pharma's application for ripretinib could bring a vital new treatment to Japanese GIST patients who have exhausted all other options.

As oncologists warn of supplement risks, one company founded by a doctor and caregiver aims to provide a safer, transparent path for cancer survivors.

The scientist behind PARP inhibitors is backing a new approach. Dr. Alan Ashworth's appointment at Leapfrog Bio signals a major push in precision oncology.

A new platform uses AI to turn complex genetic and lifestyle data into an immediate, actionable cancer prevention plan, shifting the paradigm of care.

A new collaboration aims to solve antibody reproducibility, promising to enhance diagnostic accuracy and accelerate the future of precision oncology.

With a new grant, Tessera Therapeutics is advancing its novel Gene Writing platform to engineer a scalable, single-shot cure for HIV. But can it work?

Genomics leader IDT launches its first IVD-grade NGS tests for cancer, aiming to standardize diagnostics and accelerate precision medicine.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

A top university and a global clinical research firm unite to slash drug development timelines, aiming to bring innovative therapies to patients faster.

With six top honors at a key summit, Fortis Healthcare highlights India's rapid growth as a trusted, affordable destination for advanced medical treatment.

The pharma giant is acquiring a promising 'best-in-class' PI3Kα inhibitor, SNV4818, in a move to bolster its oncology pipeline and redefine cancer care.

A novel drug designed to eliminate stubborn cancer proteins enters human trials, offering a new strategy for ALK+ lung cancer patients facing resistance.